# Study of 3D189 in Patients With Hematologic Malignancies

> **NCT05320809** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **3D Medicines** · enrollment: 15 (actual)

## Conditions studied

- Acute Leukemia
- Multiple Myeloma
- Non-Hodgkin Lymphoma
- Higher-risk Myelodysplastic Syndrome

## Interventions

- **BIOLOGICAL:** 3D189

## Key facts

- **NCT ID:** NCT05320809
- **Lead sponsor:** 3D Medicines
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-08-01
- **Primary completion:** 2026-06
- **Final completion:** 2026-12
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2025-05-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05320809

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05320809, "Study of 3D189 in Patients With Hematologic Malignancies". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05320809. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*